|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Th1/Th2 cytokines and their genotypes as predictors of hepatitis B virus related hepatocellular carcinoma显示文摘Hepatocellular carcinoma(HCC), the predominant type of primary liver cancer, is one of the most serious lifethreatening malignancies, worldwide. In majority of the cases, HCC develops after prolonged and persistent chronic liver disease. hepatitis B virus(HBV) or HCV infection is prominent etiological factors, attributing to this condition. It has been well documented that HBV, being the inducer of chronic inflammation, is the main causative agent in causing HCC, particularly in Asian countries. The HBV infection leads to a wide range of clinical symptoms from carrier state to malignancy. Cytokines being immune-modulatory molecules, are the key mediators in the defense mechanism against viral infection. In this regard, this review will detail the substantial role of key Th1: interleukin 1(IL-1), IL-2, IL-12, tumor necrosis factor-α, interferon-γ; Th2: IL-4, IL-10 and non Th1/Th2: IL-6, transforming growth factor-β1 cytokines genotypes in analyzing the variability in the clinical manifestations in an HBV-afflicted individual, which might finally, culminates into HCC. Since cytokine production is regulated genetically, the cytokine promoter region single-nucleotide polymorphisms induced changes, greatly affects the cytokine production, thus resulting into differential outcome of immune balance. | Roli Saxena Jyotdeep Kaur | 2015 | World Journal of Hepatology2015，7，11： | 50 |
| 2 | Molecular characteristics and stages of chronic hepatitis B virus infection显示文摘Hepatitis B virus (HBV) is a common viral pathogen that causes a substantial health burden worldwide. Remarkable progress has been made in our understanding of the natural stages of chronic HBV infection. A dynamic balance between viral replication and host immune response is pivotal to the pathogenesis of liver disease. Knowledge of the HBV genome organization and replication cycle can unravel HBV genotypes and molecular variants, which contribute to the heterogeneity in outcome of chronic HBV infection. Most HBV infections are spontaneously resolved in immunocompetent adults, whereas they become chronic in most neonates and infants at a great risk of developing complications such as cirrhosis and hepatocellular carcinoma (HCC). Those with chronic HBV infection may present in one of the four phases of infection: immune tolerance, immune clearance [hepatitis B eantigen (HBeAg)-positive chronic hepatitis B (CHB)], inactive carrier state, and reactivation (HBeAg-negative CHB). Understanding the dynamic nature of chronic HBV infection is crucial in the management of HBV carriers. Long-term monitoring and optimal timing of antiviral therapy for chronic HBV infection help to prevent progression of HBV-related liver disease to its later stage, particularly in patients with higher risk markers of HCC, such as serum DNA concentration, HBeAg status, serum aminotransferase, HBV genotypes, and pre-core or core mutants. | Ying-Hui Shi Chang-He Shi | 2009 | World Journal of Gastroenterology2009，15，25： | 32 |
| 3 | Enhancing the antihepatitis B virus immune response by adefovir dipivoxil and entecavir therapies显示文摘Chronicity of hepatitis B(CHB)infection is characterized by a weak immune response to the virus.Entecavir(ETV)and adefovir dipivoxil(ADV)are effective in suppressing hepatitis B virus(HBV)replication.However,the underlying immune mechanism in the antiviral response of patients treated with nucleoside or nucleotide analogs is not clearly understood.In this study,regulatory T cells(Tregs)and intracellular cytokines,including IL-2,interferon(IFN)-γ,tumor-necrosis factor(TNF)-α and IL-4,were measured prior to and at 12,24,36 and 48 weeks after treatment with ETV or ADV.The cytokines were increased from 24 to 48 weeks after treatment.Higher levels of Th1 cytokines were observed with ETV(n=29)versus ADV(n=28)treatment.By contrast,the numbers of Tregs in both groups were decreased.The altered cytokine profile and cellular component was accompanied by a decrease in HBV DNA levels in both groups,which may contribute to their therapeutic effect in CHB infection.Our findings suggest that the antiviral effect of the drugs may be attributed not only to their direct effect on virus suppression but also to their immunoregulatory capabilities. | Yanfang Jiang Wanyu Li Lei Yu Jingjing Liu Guijie Xin Hongqing Yan Pinghui Sun Hong Zhang Damo Xu Junqi Niu | 2011 | Cellular & Molecular Immunology2011，8，1： | 16 |
| 4 | 人类白细胞抗原复合体与HBV感染的相关性研究进展显示文摘乙型肝炎是全球性公共卫生问题,据估计世界约有20亿人口曾感染乙肝病毒(hepatitis B virus,HBV),其中约4亿人发展为慢性,每年有600000至1200000人死于HBV的感染。HBV感染后形成复杂的疾病谱,如亚临床感染、轻重程度不等的急性肝炎、慢性乙型肝炎(chronichepatitisB,CHB)、肝硬化(1ivercirrhosis,LC)和肝细胞癌(Hepaticcellcarcinoma,HCC)等, | 梁军 张永萍 仲英娜 | 2013 | 国际病毒学杂志2013，20，2： | 12 |
| 5 | 乙型病毒性肝炎肝细胞损伤机制的研究进展显示文摘乙型肝炎病毒(HBV)感染机体后可导致不同程度的肝脏损伤,临床上表现为急性肝炎、慢性肝炎、重型肝炎等;若炎症迁延不愈,可进一步发展为肝硬化甚至肝癌。目前乙型病毒性肝炎肝细胞损伤的具体机制尚不明确,多数学者认为机体抗HBV的免疫反应(特别是细胞免疫反应)起着关键的作用,直接决定着感染的结局。但是,随着研究的深入,非抗原特异性炎性细胞的肝细胞损伤作用越来越受到重视,除此之外,病毒自身因素(包括过度表达的病毒蛋白、HBxAg、HBSP)、细胞因子、TRAIL介导的肝细胞凋亡以及抗体依赖性细胞介导的细胞毒作用、人纤维蛋白原样蛋白2、血小板等因素也可能在乙型病毒性肝炎肝细胞损伤的发生机制中发挥一定的作用。 | 孙慧 吴金明 | 2008 | 医学综述2008，14，21： | 11 |
| 6 | Profile, spectrum and significance of hepatitisB virus genotypes in chronic HBV-infected patients in Yunnan, China显示文摘BACKGROUND: There are significant variations in the geographical distribution of hepatitis B virus (HBV) genotypes throughout the world, and some genotypes are associated with different clinical outcomes. Eight genotypes of human HBV (designated A-H) have been reported. The present study was designed to examine the distribution of HBV genotypes among patients at various stages of chronic type B liver disease in Yunnan Province, China, and to explore its significance and the relationship of HBV genotype with gender and age, clinical spectrum of chronic HBV infection, and viral replicative activity. METHODS: Serum samples from 126 patients with chronic HBV infection from Yunnan Province, including 26 chronic asymptomatic HBV carriers (ASC), 61 patients with chronic hepatitis B (CHB) (21 mild, 30 moderate and 10 severe), 20 patients with chronic fulminant hepatic failure (CFHF), 12 patients with HBV-related liver cirrhosis (LC) and 7 patients with HBV-related hepatocellular carcinoma (HCC) were analyzed using reverse dot blot (RDB) methodology, which is based on the reverse hybridization principle for HBV genotyping. The relations of HBV genotype with gender and age,clinical patterns, and serological data of the patients were analyzed. RESULTS: In this series, genotypes A, B, C, and D were found. 38.1% patients (48/126) belonged to B, 54.8% (69/126) to C, 0.8% (1/126) to D, 1.6% (2/126) to a mixture of B and C, and 1.6% (2/126) to a mixture of A and C. 3.2% patients (4/126) had unknown genotypes. No other genotypes (E, F, G, and H) were found. Genotypes B and C were predominant. There was a statistically significant difference in the distributions of genotypes C and B (χ2=7.04, P=0.008), and C was the dominant genotype in all patient categories. The rate of genotype B in the mild CHB group was significantly higher than that in the moderate and severe groups (χ2=12.16, P=0.0001; χ2=11.98, P=0.001, respectively), the ASC group (χ2=5.46, P=0.02), the CFHF group (χ2=5.53, P=0.019), and the LC/HCC group (χ2=12.13, P=0.001). The rate of genotype C in the LC/HCC group and the severe CHB group were significantly higher than that in the mild group (χ2=9.95, P=0.002; χ2=8.78, P=0.003, respectively). HBV DNA positivity and HBeAg positivity were higher in genotype C than in genotype B (χ2=9.81, P=0.002; χ2=3.85, P=0.05, respectively). The prevalence of genotype C showed an increasing trend in lowest-, middle- and highest-level groups of HBV replication (25.0%, 70.0%, and 55.6%, respectively); in contrast, the prevalence of genotype B showed an opposite trend in the same order (62.5%, 30.0%, and 37.0%, respectively). The rate of genotype C in the highest-level group of HBV replication was higher than genotype B (χ2=7.45, P=0.006). The rate of genotype C in the over-30 age group was higher than that in the below-30 age group (χ2=3.7, P=0.05). There was no difference between the sexes (P>0.05). More severe liver damage was found in genotype C than in genotype B (P<0.05). CONCLUSIONS: The predominant HBV genotypes in chronic HBV-infected patients are B and C, and C is the most prevalent genotype in Yunnan Province, China. HBV genotype C is associated with the development of more severe liver disease and a higher level of HBV viral replication, and genotype B has a relatively good progress. | Hutcha Sriplung Virasakdi Chongsuvivatwong Alan Geater | 2008 | Hepatobiliary & Pancreatic Diseases International2008，7，3： | 9 |
| 7 | Sonographic fatty liver and hepatitis B virus carrier status: Synergistic effect on liver damage in Taiwan Residents adults显示文摘AIM: To examine the epidemiology of hepatitis B virus carrier status (HBVC) and sonographic fatty liver (SFL) in Taiwan Residents adults, and to evaluate their possible interaction in inducing liver damage (LD). From an epidemiological viewpoint, we analyzed previous studies which indicated that fatty liver sensitizes host immune response to HBV infection and enhances liver damage.METHODS: A cross-sectional retrospective analysis of health records including medical history, physical examination, abdominal sonogram, blood biochemistry and hepatic virological tests. We utilized the Student's t-test, chi-square, multivariate logistic regression and synergy index to assess risks for LD.RESULTS: Among a total of 5406 Taiwan Residents adults (mean age 46.2 years, 51.5% males), the prevalence of LD, HBVC and SFL were 12.3%, 15.1% and 33.4%, respectively; 5.1% of participants had SFL plus HBVC. Multivariate logistic regression analysis demonstrated that male gender (odds ratio (OR) = 2.8, 95% confidence interval (CI): 2.3-3.5), overweight state (OR = 1.6, 95% CI: 1.3-2.0), HBVC (OR = 2.5, 95% CI: 2.0-3.1) and SFL (OR = 4.2, 95% CI: 2.2-5.3) were independently associated with LD. Synergism analysis showed that the adjusted OR for LD in adults with HBVC-alone was 3.3 (95% CI: 2.4-4.6), SFL-alone, 4.7 (95% CI: 3.7-6.1) and combined HBVC and SFL, 9.5 (95% CI: 6.8-13.3); the synergy index was 1.4 (95% CI: 1.001-2.0).CONCLUSION: In Taiwan Residents adults, SFL plus HBVC have a significant synergistic association with LD. | Yu-Cheng Lin Shu-Tin Hsiao Jong-Dar Chen | 2007 | World Journal of Gastroenterology2007，13，12： | 9 |
| 8 | Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B:A randomized controlled study显示文摘AIM: To observe the efficiency and safety of thymosin-α1 treatment in patients with hepatitis B e antigen (HBeAg) and HBV DNA positive chronic hepatitis. METHODS: Sixty-two patients were randomly divided into groups A and B. The patients in group A received subcutaneous injection of 1.6 mg thymosin-α1, twice a week (T-α1 group) for six months, and the patients in group B received 5 MU interferon alpha (IFN-α) each day for fifteen days, then three times weekly (IFN-α group) for six months. The results between two groups treated with and the group untreated with IFN-α which was followed up for 12 mo (historical control group consisting of 30 patients) were compared, and three groups were comparable between each other (P > 0.05) at baseline (age, sex, clinical history, biochemical, and serological parameters). RESULTS: At the end of treatment, complete response, which was defined as alanine aminotransferase (ALT) normalization and HBV DNA and HBeAg loss, occurred in 9 of 29 (31.0%) patients in the T-α1 group and in 15 of 33 (45.5%) patients in the IFN-α group (c2 = 1.36, P >0.05). After a follow-up period of six months, a complete response was observed in 14 of 29 (48.3%) patients in the T-α1 group and in 9 of 33 (27.3%) patients in the IFN-α group (c2 = 2.93, P > 0.05). Compared with the results observed in the historical control (HC) group untreated with IFN-α which was followed up for 12 mo, the rate of complete response was significantly higher in IFN-α group at the end of therapy (1 of 30 vs 15 of 33, c2 = 14.72, P < 0.001) and in the T-α1 group at the end of follow-up (1 of 30 vs 14 of 29, c2 = 15.71, P < 0.001). In T-α1 and IFN-α treatment groups, the area under (the plasma concentration time) curve (AUC) of negative HBV DNA and HBeAg was 34%, 17%, 31% and 19% smaller than that in the HC group. By the end of the follow- up period, the proportions of ALT normalization and negative HBV DNA in the T-α1 group were significantly higher than those in the IFN-α and HC groups. The odds of ALT normalization and negative HBV DNA at the end of the follow-up was three-fold higher in the T-α1 group than in the IFN-α group. Unlike IFN-α, T-α1 was well tolerated by all patients, and no side effects appeared in T-α1 group.CONCLUSION: The results suggest that a 6-mo course of T-α1 therapy is effective and safe in patients with chronic hepatitis B. T-α1 is able to reduce HBV replication in patients with chronic hepatitis B. Furthermore, T-α1 is better tolerated than IFN-α and can gradually induce more sustained ALT normalization and HBV DNA and HBeAg loss. However, a response rate of 48.3% is still less ideal. A more effective therapeutic approach warrants further study. | Jing You Lin Zhuang Hong-Ying Cheng Shou-Ming Yan Lan Yu Jun-Hua Huang Bao-Zhang Tang Meng-Ling Huang Yong-Liang Ma Virasakdi Chongsuvivatwong Hutcha Sriplung Alan Geater Yan-Wei Qiao Rong-Xue Wu | 2006 | World Journal of Gastroenterology2006，12，41： | 8 |
| 9 | 一过性HBV感染献血者的追踪观察显示文摘目的通过对一过性HBV感染献血者的追踪观察和共同特征的分析,寻求可靠的鉴别诊断方法。方法对2010年12月2日-2012年2月29日共计72 830份血液标本进行HBsAg、HCV抗体、HIV抗体、梅毒特异性抗体4项ELISA法双试剂检测、谷丙转氨酶测定,同时进行HBV、HCV、HIV的三联检核酸定性检测,核酸定性检测阳性者做核酸鉴别试验。对筛选出的ALT正常、HBsAg(-)、HBV DNA阳性者进行补充实验和追踪检测。补充实验为电化学发光法测定乙肝两对半(HBsAg、抗-HBs、抗-HBc、HBeAg和抗-HBe)和核酸定量检测,追踪检测包括核酸定性、定量和乙肝两对半。结果共检出ALT正常、HBsAg(-)且HBV DNA(+)的献血者44例,追踪到32例(72.7%)。其中,一过性HBV感染8例(25%),平均年龄25.6岁,男性6人,女性2人。平均追踪时间为283.3 d。全部献血者出现核酸检测阴转,平均阴转测定时间为197.5 d。整个追踪过程中HBsAg检测始终为阴性,anti-HBs和/或anti-HBc发生阳转,ALT最高为48 IU/ml,均无明显症状体征。结论核酸检测、HBsAg、anti-HBs和anti-HBc 4项指标的追踪检测有利于一过性HBV感染的鉴别。 | 于志军 邓雪莲 | 2013 | 实用预防医学2013，20，4： | 7 |
| 10 | Profiling the repertoire of T-cell receptor beta-chain variable genes in peripheral blood lymphocytes from subjects who have recovered from acute hepatitis B virus infection显示文摘T 房间受体贝它链的侧面变量(TRBV ) 基因通常与病毒感染或癌症在题目扭曲。融化的基因光谱模式(GMSP ) 能被用来决定 TRBV 基因家庭的侧面。从从尖锐肝炎 B 病毒感染(AHI ) 恢复了的题目在外部血淋巴细胞探索 TRBV 家庭的肖像,外部血 mononuclear 房间(PBMC ) 被分开并且进一步排序 + 和 CD8 +T 房间子集进 CD4。TRBV 的分子的特征补足的决定区域 3 (CDR3 ) 主题用 GMSP 分析被决定。当 GMSP 侧面显示出一座单个山峰时, monoclonally 扩展的 TRBV 基因被克隆并且定序。多重 TRBV 基因的扭曲的扩大在 CD4 + 和 CD8 +T 房间子集和 PBMC 之中被观察。在 CD8 +T 房间子集的 monoclonally 扩展的 TRBV 基因的频率比 CD4 +T 房间子集和 PBMC 的显著地高。比作 TRBV 基因家庭, TRBV11, BV15 和 BV20 的另外的成员主要在恢复 AHI 题目在外部血淋巴细胞的全部剧目被表示。TRBV5.1 和 BV20 CDR3 的相对保存的氨基酸主题也在 CD4 + 和 CD8 +T 房间子集被检测。这些结果在恢复 AHI 题目表明多重偏导的 TRBV 家庭的存在。特别从 CD8 +T 房间子集, TRBV11, BV15 和 BV20 可能与有 AHI 的题目的致病相关。有相对保存的 CDR3 主题的优先地选择的 TRBV5.1 和 BV20 可以是为长期的 HBV 感染的个性化的处理的潜在的目标。 | Jiezuan Yang | 2014 | Cellular & Molecular Immunology2014，11，4： | 6 |
| 11 | 抗病毒治疗过程中慢性乙型肝炎患者外周血辅助性T细胞因子的变化显示文摘目的观察慢性乙型肝炎(CHB)患者外周血辅助性T细胞因子水平在抗病毒治疗过程中的变化,进一步探讨其与CHB发病的关系。方法在33例CHB患者采用恩替卡韦抗病毒治疗过程的不同时期,采用ELISA法检测其外周血IL-2、IL-6、IL-10、IFNγ和TNF-α水平,并同时检测患者肝功能。治疗前后细胞因子水平比较采用单因素方差分析,细胞因子水平变化与ALT、HBVDNA水平间行相关性分析。结果IFNγ水平在治疗前及治疗12、24、48周分别为(5.98±2.77)、(5.95±3.37)、(2.93±2.15)、(9.29±4.65)pg/mL(F=3.845,P〈0.05),与ALT呈正相关(r=0.396,P〈0.05);TNF—α及IL-10治疗前后呈逐渐下降趋势,各时期间差异有统计学意义(F=20.156,16.695;均P〈0.05),与ALT均呈正相关(r=0.354,0.316;均P〈0.05),与HBV DNA也均呈正相关(r=0.382,0.386;均P〈0.05);IL2、IL-6治疗前后各时期间差异无统计学意义(F=0.010,0.932;均P〉0.05)。治疗前及治疗后各时期ALT、HBV DNA水平间差异有统计学意义(F=17.69,198.98;均P%0.05),均随抗病毒治疗时间的延长逐渐降低,且两者间呈正相关(r=0.581,P〈0.05)。结论IL-10、IFNγ、TNF-α等细胞因子可能参与CHB病理过程,并与肝炎的病情变化密切相关,抗病毒过程中检测其血浆浓度有助于了解机体免疫情况,评价抗病毒药物疗效。 | 赵学辉 杨介钻 胡云良 鲁海峰 魏丽 王保红 李兰娟 | 2011 | 中华传染病杂志2011，39，11： | 6 |
| 12 | 乙型肝炎病毒感染与非霍奇金淋巴瘤相关性的研究显示文摘目的:通过比较非霍奇金淋巴瘤(NHL)患者与肺癌患者乙型肝炎病毒(HBV)感染率的差异,进一步探讨HBV感染与NHL之间的关系。方法:回顾性分析2000-01-2009-02在浙江省肿瘤医院住院治疗的1279例NHL患者和随机抽取同期住院的1340例肺癌患者HBV抗原抗体表达情况,并判断其差异性。结果:NHL患者HBsAg阳性率较肺癌患者差异有统计学意义(χ2=13.30,P=0.000),其HBsAg、HBeAb和HBcAb及HBsAg、HBeAg和HBcAb阳性率均明显高于肺癌患者(χ2=4.60,P=0.032;χ2=45.09,P=0.000);两组之间抗体阳性率差异均无统计学意义。同时B细胞性NHL患者的HBsAg阳性率明显高于肺癌患者(χ2=22.18,P=0.000);而T细胞性NHL患者与肺癌患者的HB-sAg阳性率差异无统计学意义,χ2=1.03,P=0.309。在NHL两亚型之间,B细胞性NHL患者的HBsAg阳性率明显高于T细胞性NHL患者(χ2=5.06,P=0.024)。结论:NHL患者HBV感染率明显高于肺癌患者,B细胞性NHL患者的感染率高于T细胞性NHL;提示HBV持续感染可能在NHL尤其在B细胞性NHL发病中起重要作用;为制定NHL的防治策略提供了参考依据。 | 罗吕宏 范云 黄志熠 余海峰 | 2010 | 中华肿瘤防治杂志2010，17，18： | 6 |
| 13 | Hepatitis-related hepatocellular carcinoma: Insights into cytokine gene polymorphisms显示文摘Hepatocellular carcinoma(HCC) is a primary liver cancer, which is one of the most prevalent cancers among humans. Many factors are involved in the liver carcinogenesis as lifestyle and environmental factors. Hepatitis virus infections are now recognized as the chief etiology of HCC; however, the precise mechanism is still enigmatic till now. The inflammation triggered by the cytokine-mediated immune response, was reported to be the closest factor of HCC development. Cytokines are immunoregulatory proteins produced by immune cells, functioning as orchestrators of the immune response. Genes of cytokines and their receptors are known to be polymorphic, which give rise to variations in their genes. These variations have a great impact on the expression levels of the secreted cytokines. Therefore, cytokine gene polymorphisms are involved in the molecular mechanisms of several diseases. This piece of work aims to shed much light on the role of cytokine gene polymorphisms as genetic host factor in hepatitis related HCC. | Mahmoud Fathy Dondeti Eman Anwar El-Maadawy Roba Mohamed Talaat | 2016 | World Journal of Gastroenterology2016，22，30： | 4 |
| 14 | 外周血CD4^+CD25^+Foxp3^+调节性T细胞与HCV感染的相关性显示文摘CD4^+CD25^+调节性T淋巴细胞(T regulatory lymphoey cell,Treg)可抑制T细胞免疫反应,正常外周血中CD4^+CD25^+Treg约占CD4^+T细胞的5%~10%。越来越多的研究表明CD4^+CD25^+Treg在人类体内对诱导和维持免疫耐受起着重要作用且与多种疾病的免疫有关[1-6]。CD25既是CD4^+CD25^+Treg的特征性标志,又是T细胞激活的标志,因此,不能仅借助CD25将两者鉴别开来,而Foxp3是Treg的主要转录因子,可调控Treg的生长发育与功能效应[6-7],故以CD4^+CD25^+Foxp3^+标志Treg更为可靠。本研究旨在探讨HCV感染时外周血中CD4^+CD25^+Foxp3^+Treg出现的频率及其与HCVRNA含量的相关性。 | 蒋自卫 | 2019 | 肝脏2019，24，9： | 3 |
| 15 | 乙型肝炎病毒感染的病理机制显示文摘本文简介了乙型肝炎病毒(HBV)的特点及其感染自然史,论述了HBV的免疫介导和直接作用的肝损伤机制,以及尚存的问题亟待阐明,这不仅能提高对病理机制的认识,同时也为防治提供新思路。 | 刘成海 | 2012 | 现代消化及介入诊疗2012，17，5： | 3 |
| 16 | 慢性乙型肝炎患者的细胞免疫显示文摘 | 王媛媛 韩涛 | 2008 | 武警医学院学报2008，17，4： | 2 |
| 17 | CD_4^+CD_(25)^+Foxp3^+调节性T细胞在乙型肝炎病毒感染慢性化中的作用显示文摘目的探讨CD4+CD25+Foxp3+调节性T细胞(Treg)在慢性乙型肝炎病毒(HBV)感染中的免疫调节作用,分析HBV感染的慢性化是否与外周血中CD4+CD25+Foxp3+调节性T细胞的表达率有关。方法本院2008年6月—2009年5月收治的HBV感染者60例,其中乙型肝炎活动期患者30例,HBV携带者30例,选择同期门诊体检者30例为对照者。应用流式细胞仪检测外周血CD4+CD25+Foxp3+调节性T细胞表达,结合HBV感染者临床情况分析各组外周血中CD4+CD25+Foxp3+调节性T细胞的比率与血清HBeAg和HBVDNA含量的关系。结果 HBV感染及HBV携带者外周血CD4+CD25+Foxp3+调节性T细胞表达率较健康对照组显著增高[(8.68%±1.23)%与(1.38±0.6)4%,P<0.01];慢性乙肝携带组与慢性乙肝恢复组比较,外周血CD4+CD25+Foxp3+调节性T细胞的表达率差异有统计学意义[(8.68±1.23)%与(2.63±1.38)%,P<0.01];HBVDNA病毒含量及HBeAg含量与外周血CD4+CD25+Foxp3+调节性T细胞的表达率之间存在正相关(P<0.01)。结论 HBV感染者外周血CD4+CD25+Foxp3+调节性T细胞水平与疾病进展明显相关,Treg在慢性乙型肝炎携带者中明显增高,并与病毒载量相关,提示Treg在慢性乙型肝炎中担负着重要的免疫调节作用,可能是造成乙肝病毒感染慢性化的重要因素。 | 蒋自卫 赵红 | 2013 | 实用临床医药杂志2013，17，21： | 2 |
| 18 | 乙型肝炎病毒父婴传播易感因素与预防显示文摘乙型肝炎病毒(HBV)垂直传播除了众所周知的母子传播外,还包括父子间传播,HBV在父、子女间是否存在及存在怎样的遗传传递目前还知之甚少,对HBV父、子女间遗传传递及易感因素的研究将成为研究HBV传播的一个热点。 | 罗昊翔 冉光鑫 | 2014 | 中国医学创新2014，11，6： | 2 |
| 19 | 转化生长因子-α在肝脏疾病中的研究显示文摘转化生长因子_α(TGF_α)是一种参与调节正常细胞和肿瘤细胞增殖、分化的细胞因子,是肝细胞增殖分化过程中必不可少的有丝分裂原。近年来,TGF_α和肝脏病的关系已被证实,但是具体机制还不明确。 | 柯迎春 罗光汉 | 2006 | 国际流行病学传染病学杂志2006，33，5： | 2 |
| 20 | IL-4基因多态性与HBV遗传易感性的研究显示文摘目的探讨白介素4(interleukin-4,IL-4)基因的单核苷酸多态性(single nucleotide polymorphisms,SNPs)与皖汉族人群乙型肝炎病毒(hepatitis B virus,HBV)遗传易感性的关系。方法采用病例对照研究,501位慢性乙型肝炎(chronic hepatitis B,CHB)患者和301位急性自限性HBV感染者分别组成病例组和对照组;采用多重单碱基延伸SNP分型技术(Multiplex SNaPshot),检测两组人群的IL-4基因rs2227284G/T、rs2243283C/G和rs2243288A/G 3个标签SNPs位点的单核苷酸多态性,分析两组间的等位基因频率、单体型频率、基因型是否存在统计学差异。结果 IL-4基因3个多态位点的基因型频率在两组间差异均无统计学意义(均有P>0.05);IL-4基因3个态位点最小等位基因及其频率在两组间差异均无统计学意义(均有P>0.05);4个单体型GCA、TCA、TCG及TGG两组间差异均无统计学意义(均有P>0.05)。结论皖汉族人群中IL-4基因的3个tagSNPs(rs2227284,rs2243283和rs2243288)位点的基因多态性与HBV感染的基因易感性可能无相关性。 | 周琴 郜玉峰 赵小苗 潘发明 李旭 | 2014 | 中华疾病控制杂志2014，18，10： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员